Abstract
By opioid is meant any drug, regardless of chemical structure, that acts like morphine. The term opioid is preferred to the older term, opiate, for two reasons: first, because opiate implies presence in or derivation from opium, which indeed contains the analgesic drugs morphine and codeine but also contains thebaine, a strong stimulant (convulsive) drug with minimal analgesic properties, and also papaverine and noscapine, which have no analgesic actions; and second, because of a host of purely synthetic drugs with actions qualitatively similar to those of morphine and codeine that, unlike the analgesics found in opium or derived therefrom, lack the phenanthrene nucleus (e.g., methadone, meperidine, d-propoxyphene). Opium is prepared from the sap of the poppy Papaver somniferum and contains about 10% by weight of morphine and about 0.5% by weight of codeine. Analgesic compounds that are derived from morphine and that retain the phenanthrene nucleus and are classed as opioids include heroin (diacetylmorphine), hydromorphone (Dilaudid), oxymorphone (Numorphan), and oxycodone (Percodan). Purely synthetic analgesic compounds that lack the phenanthrene nucleus but are classed as opioids include methadone (Dolophine), meperidine (Demerol), d-propoxyphene (Darvon), levorphanol (Levo-Dromoran), and phenazocine (Prinadol). In man, the analgesic potencies of these drugs relative to morphine (all drugs given subcutaneously) are codeine, one-twelfth; heroin, 2–3 times; hydromorphine, 6–8 times; oxymorphone, 7–10 times; oxycodone, two-thirds to equipotent; methadone, equipotent; meperidine, one-tenth to one-eighth; levorphanol, 2–3 times; and phenazocine, 3 times. By the oral route, 65 mg of d-propoxyphene is equivalent to 32–45 mg of codeine for analgesia, but 32 mg of d-propoxyphene may be no more effective than placebo. A newer synthetic compound, pentazocine (Talwin), exerts some morphinelike effects (analgesia, respiratory depression, sedation) in doses of 30–50 mg given parenterally (equivalent to 10 mg of morphine) or of 50 mg given orally (equivalent to 60 mg of codeine); at higher doses, pentazocine also produces dysphoric and psychotomimetic effects that can be reversed by naloxone, but not by nalorphine. In addition, pentazocine has weak opioid-antagonistic actions and can precipitate abstinence phenomena in morphine-dependent individuals. Though not in clinical use, etorphine (Immobilon), an opioid derived from oripavine and ultimately from thebaine, is of interest because of its extreme potency. In man, it is about 400 times as potent as morphine, though its duration of action is much shorter; in animals, its potency is even greater than in man, and it is used for immobilizing large game animals (Harthoorn & Bligh, 1965). Although of all these opioid analgesics, heroin is the most widely abused in the United States, its pharmacological effects (including the development of tolerance and physical dependence) do not differ qualitatively from those of morphine. The same is true also of hydromorphone, oxymorphone, oxycodone, levorphanol, phenazocine, and methadone, but the pharmacological effects of meperidine, d-propoxyphene, and pentazocine present more prominent differences with regard to “toxicity” and/or physical dependence. The pharmacological effects of morphine serve here as a prototype of the actions of opioids in general, and deviations from this prototype are noted for some particular opioid analgesics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allen, C. R., Murphy, M. A., and Meek, W. J., 1945, The action of morphine in slowing the heart rate of unconditioned dogs, Anesthesiology 6: 149–153.
Andrews, H. L., 1943, Changes in the electroencephalogram during a cycle of morphine addiction, Psychosom. Med. 5: 143–147.
Andrews, H. L., and Himmelsbach, C. K., 1944, Relation to the intensity of the morphine abstinence syndrome to dosage, J. Pharmacol. Exp. Ther. 81: 288–293.
Andrews, H. L., and Workman, W., 1941, Pain threshold measurements in the dog, J. Pharmacol. Exp. Ther. 73: 99–103.
Archer, S., Albertson, N. F., Harris, L. S., Pierson, A. K., Bird, J. G., Keats, A. S., Telford, J., and Papadopoulos, C. N., 1962, Narcotic antagonists as analgesics, Science 137: 541–543.
Archer, S., Albertson, N. F., Harris, L. S., Pierson, A. K., and Bird, J. G., 1964, Pentazocine: Strong analgesics and analgesic antagonists in the benzomorphan series, J. Med. Chem. 7: 123–127.
Arduini, A., and Arduini, M. G., 1954, Effect of drugs and metabolic alterations on brain stem arousal mechanism, J. Pharmacol. Exp. Ther. 110: 76–85.
Bauer, R. O., and Pearson, R. G., 1956, The effects of morphine-nalorphine mixtures on psychmotor performance, J. Pharmacol. Exp. Ther., 117: 258–264.
Bickerman, A. A., and Barach, A. L., 1954, The experimental production of cough in human subjects induced by citric acid aerosis: Preliminary studies on the evaluation of antitussive agents, Amer. J. Med. Sci. 228: 156–163.
Blumberg, H., and Dayton, H. B., 1972, Narcotic antagonist studies with EN-1639A (Ncyclopropylmethylnoroxymorphone hydrochloride), in Fifth International Congress on Pharmacology, San Francisco, 23–28 July 1972, Abstracts of Volunteer Papers, p. 23.
Blumberg, H., Dayton, H. B., George, M., and Rapaport, D. N., 1961, N-allylnoroxymorphone: A potent narcotic antagonist, Fed. Proc. 20: 311.
Bremer, F., 1937, Différence d’action de la narcose éthérique et du sommeil barbiturique sur les réactions sensorielles acoustiques du cortex cérébral: Signification de cette différence en ce qui concerne la mécanisme du sommeil, Compt. Rend. Soc. Biol. Paris 124: 848–852.
Briggs, F. N., and Munson, P. L., 1954, Suppression of the release of adrenocortictrophic hormone (ACTH) my morphine, J. Pharmacol. Exp. Ther. 110: 7–8.
Brooks, C. McC., and Peck, M. E., 1940, Effect of various cortical lesions on development of placing and hopping reactions in rats, J. Neurophysiol. 3: 66–72.
Brooks, C. McC., Goodwin, R., and Willard, H. N., 1941, The effect of various brain lesions on morphine induced hyperglycemia and excitement in the cat, Amer. J. Physiol. (Proc.) 133: 226–227.
CoTui, F. W., DeBodo, R. C., and Bengalia, A. E., 1937, Morphine Hyperglycemia, J. Pharmacol. Exp. Ther. 61: 48–57.
D’Amour, F. E., and Smith, D. L., 1941, A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther. 72: 74–79.
DeBodo, R. C., 1944, The antidiuretic of morphine and its mechanism, J. Pharmacol. Exp. Ther. 82: 74–85.
DeBodo, R. C., and Brooks, C. McC., 1937, The effects of morphine on blood sugar and reflex activity in the chronic spinal cat, J. Pharmacol. Exp. Ther. 61: 82–88.
De Noraquo, N., 1969, The hallucinatory effect of pentazocine (Talwin), J. Amer. Med. Ass. 210: 502.
Drew, J. H., Dripps, R. D., and Comroe, J. H., 1946, Clinical studies on morphine. II. The effect of morphine upon the circulation of man and upon the circulatory and respiratory responses to tilting, Anesthesiology 7: 4–61.
Dripps, R. B., and Dumke, P. R., 1943, The effect of narcotics on the balance between central and chemoreceptor control of respiration, J. Pharmacol. Exp. Ther. 77: 290–300.
Drug and Theraputic Information, Inc. (New York), 1970, Propoxyphene hydrochloride (Darvon) and Darvon compounds, The Medical Letter 12(2), Jan. 23.
Eckenoff, J. E., Elder, J. D., and King, B. D., 1951, The effect of N-allylnormorphine in treatment of opiate overdose, Amer. J. Med. Sci. 222: 115–117.
Eckenhoff, J. E., Elder, J. D., and King, B. D., 1952, N-allylnormorphine in the treatment of morphine or Demerol narcosis, Amer. J. Med. Sci. 223: 191–197.
Eddy, N. B., and May, E. L., 1973, The search for a better analgesic, Science 181: 407–414.
Eisenman, A. J., Fraser, H. F., and Brooks, J. W., 1961, Urinary excretion and plasma levels of 17-hydroxycorticosteroids during a cycle of addiction to morphine, J. Pharmacol. Exp. Ther. 132: 226–231.
Eisenman, A. J., Sloan, J. W., Martin, W. R., Jasinski, D. R., and Brooks, J. W., 1969, Catecholamine and 17-hydroxycorico-steroid excretion during a cycle of morphine dependence in man, J. Psychiat. Res. 7: 19–28.
Fischlewitz, J., 1948, Über den Angriffspunkt des Morphins am Atmungszentrum, Helv. Physiol. Acta. 6: 455–461.
Foldes, F. F., Lunn, J. N., Moore, J., and Brown, I. M., 1963, N-allylnoroxymorphone: A new potent narcotic antagonist, Amer. J. Med. Sci. 245: 23–30.
Food and Drug Administration, Pentazocine abuse rises—Schedule IV status proposed, 1978–1979, FDA Drug Bull. 8(6):34.
Food and Drug Administration, 1979, Fatalities due to propoxyphene, FDA Drug Bull. 9 (1): 2.
Fraser, H. F., and Isbell, H., 1952, Comparative effects of 20 mg., of morphine sulfate on non-addicts and former addicts, J. Pharmacol. Exp. Ther. 105: 498–502.
Fraser, H. F., and Isbell, H., 1960, Human pharmacology and addiction liability of dl - and d-propoxyphene, U. N. Bull. Narcotics 12: 9–14.
Fraser, H. F., and Rosenberg, D. E., 1964, Studies of human addiction liability of 2’hydroxy-5, 9-dimethy-2-(3,3-dimethylallyl)-6,7-benzomorphan (WIN 20,228): Weak narcotic antagonist, J. Pharmacol. Exper. Ther, 143: 149–156.
Fraser, H. F., Wikler, A., Eiseman, A. J., and Isbell, H., 1952, Use of N-allylnormorphine in treatment of methadone poisoning in man: Report of two cases, J. Amer. Med. Ass. 148: 1205–1207.
Fraser, H. F., Nash, T. L., Van Horn, G. D., and Isbell, H., 1954, Use of miotic effect in evaluating analgesic drugs in man, Arch. Int. Pharmacodyn. Ther. 98: 443–451.
Fraser, H. F., Van Horn, G. D., and Isbell, H., 1956, Studies on N-allylnormorphine in man: Antagonism to morphine and heroin and effects of mixtures of N-allylnormorphine and morphine, Amer. J. Med. Sci. 231: 1–8.
Fraser, H. F., Isbell, H., and Van Horn, G. D., 1957, Effects of morphine as compared with a mixture of morphine and diaminphenylthiazole (Daptazole), Anesthesiology 18: 53 1535.
Fraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., and Isbell, H., 1961, Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) A short-term “direct” addiction test, J. Pharmacol. Exp. mer. 133: 371–387.
George, R., and Way, E. L., 1955a, Adrenal cortical response of normal, adrenal demedullated and hypophysectomized rats to morphine and methadone, J. Pharmacol. Exp. Ther. 113: 23.
George, R., and Way, E. L., 1955b, Studies on the mechanism of pituitary-adrenal activation by morphine, Brit. J. Pharmacol. Chemother. 20: 260–264.
George, R., and Way, E. L., 1959, The role of the hypothalamus in pituitary-adrenal activation and antidiuresis by morphine, J. Pharmacol. Exp. Ther. 125: 111–115.
Goetz, E. L., and Bain, R. V., 1974, Neonatal withdrawal symptoms associated with maternal use of pentazocine, J. Pediatr. 84: 887–888.
Gray, G. W., and Beckman, H., 1956, Effects of certain analgesic and analgesic-antagonist drugs on intestinal motility, J. Pharmacol. Exp. Ther. 116: 25.
Haertzen, C. A., and Hooks, N. T., 1969, Changes in personality and subjective experience associate with the chronic administration of opiates, J. Nerv. Ment. Dis. 148: 606–614.
Hambourger, W. E., 1940, The excitant action of morphine on the cat, J. Pharmacol. Exp. Ther. (Abstract) 69: 287.
Harris, L. S., and Pierson, A. K., 1964, Some narcotic antagonists in the benzomorphan series, J. Pharmacol. Exp. Ther. 143: 141–148.
Harthoorn, A. M., and Bligh, J., 1965, The use of a new oripavine derivative with potent morphine-like activity for the restraint of hoofed wild animals, Res. Vet. Sci.6: 290–299.
Hemingway, A., 1938, The effect of morphine on the skin and rectal temperatures of dogs as related to thermal polypnea, J. Pharmacol. Exp. Ther. 63: 414–420.
Henderson, V. W., and Rice, H. V., 1939, The action of certain drugs on respiratory reflexes, J. Pharmacol. Exp. Ther. 66: 336–349.
Himmelsbach, C. K., 1941, Studies on the relation of drug addiction to the autonomic nervous system: Results of cold pressor tests, J. Pharmacol. Exp. Ther. 73: 91–97.
Himmelsbach, C. K., 1942a, Clinical studies on drug addiction. Physical dependence, withdrawal and recovery, Arch. Int. Med. 69: 766–722.
Himmelsbach, C. K., 1942b, Studies of the addiction liability of “Demerol” (D-140), J. Pharmacol. Exp. Ther. 75: 54–68.
Himmelsbach, C. K., 1943, Further studies of the addiction liability of Demerol (1methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester hydrochloride), J. Pharmacol. Exp. Ther. 79: 5–9.
Himmelsbach, C. K., 1944, Studies on the relation of drug addiction to the autonomic nervous system: results of tests of peripheral blood flow, J. Pharmacol. Exp. Ther. 80: 343–353.
Himmelsbach, C. K., Andrews, H. L., Felix, R. H., Oberst, F. W., and Davenport, L., 1940, Studies on codeine addiction, Publ. Health Rep. Suppl. 158.
Houde, R. R., and Wikler, A., 1951, Delineation of the skin-twitch response in dogs and the effects thereon on morphine, theiopental and mephenesin, J. Pharmacol. Exp. Ther. 103: 236–242, 1951.
Huggins, R. A., Handley, C. A., and La Forge, M., 1949, Effects of morphine, codiene and dilaudid on blood flow, J. Pharmacol. Exp. Ther. 95: 318–322.
Irwin, S., Houde, R. W., Bennett, D. R., Hendershot, L. C., and Seevers, M. H., 1951, The effects of morphine, methadone, and meperidine on some reflex responses of spinal animals to nociceptive stimulation, J. Pharmacol. Exp. Ther. 101: 132–143.
Isbell, H., 1947, Effect of morphine addiction on blood, plasma and “extracellular” fluid volumes in man, Pub. Health Reports 62: 1499–1513.
Isbell, H., 1956, Attempted addiction to nalorphine, Fed. Proc. 15: 442.
Isbell, H., Eisenman, A. J., Wikler, A., and Frank, K., 1948a, The effects of single doses of 6-dimethylamino-4, 4-diphenyl-3-heptanone (Amidon, methadon, or “10820”) on human subjects, J. Pharmacol. Exp. Ther. 92: 83–89.
Isbell, H., Wikler, A., Eisenman, A. J., Daingerfield, M., and Frank, K., 1948b, Liability of addiction of 6-dimethylamino-4, 4-diphenyl-3-heptanone (methodon, amidone or “10820”) in man, Arch. Int. Med. 82: 362–396.
Jasinski, D. R., 1973, Assessment of the dependence liability of opiates and sedative hypnotics, in Psychic Dependence ( L. Goldberg and F. Hoffmeister, Eds.), p. 164. Springer-Verlag, New York.
Jasinski, D. R., Martin, W. R., and Haertzen, C. A., 1967, The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone), J. Pharmacol. Exp. Ther. 157: 420–426.
Karliner, J. S., 1967, Propoxyphene hydrochloride poisoning: Report of a case treated with peritoneal dialysis, J. Amer. Ass. 199: 1006–1009.
Kay, D. C., 1975a, Human sleep and EEG through a cycle of methadone dependence, Electroenceph. Clin. Neurophysiol. 38: 35–43.
Kay, D. C., 1975b, Human sleep during chronic morphine intoxication, Psychopharmacologia 44: 117–124.
Kay, D. C., Eisenstein, R. B., and Jasinski, D. R., 1949, Morphine effects on human REM state, waking state and NREM sleep, Psychopharmacologia 14: 404–416.
Keats, A. S., and Telford, J., 1956, Nalorphine, a potent analgesic in man, J. Pharmacol. Exp. Ther. 117: 190–196.
Lasagna, L., 1965, Drug interaction in the field of analgesic drugs, Proc. Roy. Soc. Med. 58: 978–983.
Lasagna, L., and Beecher, H. K., 1954, The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man, J. Pharmacol. Exp. Ther. 112: 356–363.
Lee, H. K., and Wang, S. C., 1975, Mechanism of morphine-induced miosis in the dog, J. Pharmacol. Exp. Ther. 192: 415–431.
Leimdorfer, A., 1948, An electroencephalographic analysis of the action of amidone, morphine and strychnine on the central nervous system. Arch. Int. Pharmacodyn. Ther. 76: 153–162.
Lindsley, D. B., Bowden, J. W., and Magoun, H. W., 1949, Effect upon the EEG of acute injury to the brain stem activating mechanism, Electroencephalog. Clin. Neurophysiol. 1: 475–485.
Lotti, V. J., Lomax, P., and George, R., 1965a, N-allylnormorphine antagonism of the hypothermic effect of morphine in the rat following intracerebral and systemic administration, J. Pharmacol. Exp. Ther. 150: 420–425.
Lotti, V. J., Lomax, P., and George, R., 1965b, Temperature responses in the rat following intracerebral microinjection of morphine, J. Pharmacol. Exp. Ther. 150: 135–139.
Lotti, V. J., Lomax, P., and George, R., 1966, Acute tolerance to morphine following systemic and intracerebral injection in the rat, Int. J. Neuropharmacol. 5: 35–42.
Lotti, V. J., Kokka, N., and George, R., 1969, Pituitary-adrenal activation following intrahypothalamic microinjection of morphine, Neuroendocrinology 4: 326–332.
Marri, R., and Hauss, W. H., 1939, Sinus carotidien et réflexes respiratoires: Influences de l’hypoxemie, de l’hypercapnie, de la saignée, de l’hyperthermie, de l’ésérine, de la morphine, du véronal et de l’évipan sur les réflexes respiratoires déclenchés par les variations de la pression sanguine au niveau du sinus carotidien, Arch. Int. Pharmacodyn. Thér. 63: 449–469.
Martin, W. R., 1967, Opioid antagonists, Pharmacol. Rev. 19: 463–521.
Martin, W. R., and Fraser, H. F., 1961, A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in post-addicts, J. Pharmacol. Exp. Ther. 133: 388–399.
Martin, W. R., and Gorodetzky, C. W., 1965, Demonstration of tolerance to and physical dependence on N-allylnormorphine (nalorphine), J. Pharmacol. Exp. Ther. 150: 437–442.
Martin, W. R., and Jasinski, D. R., 1969, Physiological parameters of morphine dependence in man: Tolerance, early abstinence, protracted abstinence, J. Psychiat. Res. 7: 9–17.
Martin, W. R., Wilder, A., Eades, C. G., and Pescor, F. R., 1963, Tolerance to and physical dependence on morphine in the rat, Psychopharmacologia 4: 247–260.
Martin, W. R., Fraser, H. F., Gorodetzky, C. W., and Rosenberg, D. E., 1965, Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl2’-hydroxy-5, 9-dimethyl-6, 7 benzomorphan (cyclazocine, WIN-20, 740, ARC II-C-3), J. Pharmacol. Exp. Ther. 150: 426–436.
Martin, W. R., Gorodetzky, C. W., and McClane, T. K., 1966, An experimental study in the treatment of narcotic addicts with cyclazocine, Clin. Pharmacol. Ther. 7: 455–465.
Martin, W. R., Jasinski, D. R., Sapira, J. D., Flanary, H. G., Kelly, O. A., Thompson, A. K., and Logan, C. R., 1968, The respiratory effects of morphine during a cycle of dependence, J. Pharmacol. Exp. Ther. 62: 182–189.
Martin, W. R., Jasinski, D. R., and Mansky, P. A., 1973, Naltrexone, an antagonist for the treatment of heroin dependence, Arch. Gen. Psychiat. 28: 784–791.
Masserman, J. H. 1939, Effects of morphine sulfate on hypothalamus of cat, Proc. Soc. Exp. Biol. Med. (N.Y.) 42:315–317.
McCawley, E. L., Hart, E. R., and Marsh, D. F., 1941, The preparation of N-allylnormorphine, J. Amer. Chem. Soc. 63: 314.
McCrea, F. D., Eadie, G. S., and Morgan, J. E., 1942, The mechanism of morphine miosis, J. Pharmacol. Exp. Ther. 74: 239–246.
Meissner, R. 1923, Ueber atmungserregende Heilmittel, Z. gesamte Exp. Med. 31: 159–214.
Nilsen, O. L., 1961, Studies on algesimetry by electrical stimulation of the mouse tail, Acta Pharmacol. Toxicol. 18: 10–22.
Orahovats, P. D., Winter, C. A., and Lehman, E. G., 1953, The effect of N-allylnormorphine upon the development of tolerance to morphine in the albino rat, J. Pharmacol. Exp. Ther. 109: 413–416.
Pearl, J., Stander, H., and McKean, D. B., 1969, Effects of analgesics and other drugs on mice in phenylquinone and rotarod tests, J. Pharmacol. Exp. Ther. 167: 9–13.
Perrine, T. D., Atwell, L., Tice, I. B., Jacobson, A. E., and May, E. L., 1972, Analgesic activity as determined by the Nilsen method, J. Pharm. Sci. 61: 86–88.
Pohl, J., 1915, Ober das N-allylnorcodein, einen Antagonisten des Morphins, Z. exp. Path. Ther. 17: 370–382.
Richter, C. P., and Paterson, A. S., 1932, On the pharmacology of the grasp reflex, Brain 55: 391–396.
Rovenstine, E. A., and Cullen, S. C., 1939, Anesthetic management of patients with hyperactive carotid sinus reflex, Surgery 6: 167–176.
Sandoval, R. G., and Wang, R. I. H., 1969, Tolerance and dependence on pentazocine, New Engl. J. Med. 280: 1391–1392.
Sawyer, C. H., Critchlow, B. V., and Barraclough, C. A., 1955, Mechanisms of blockage of pituitary activation in the rat by morphine, atropine and barbiturates, Endocrinology 57: 345–354.
Scanlon, J. W., 1974, Pentazocine and neonatal withdrawal symptoms, J. Pediatr. 85: 735–736.
Schmidt, C. F., 1940, Effect of carotid sinus and carotid body reflexes upon respiration, Anesthesiol. Analgesia 19: 261–271.
Schrappe, 0., 1959, “Physical dependence” nach chronischer Verabreichung von N-allylnormorphin, Arzneim. -Forsch. 9:130–132.
Seevers, M. H., and Deneau, G. A., 1963, Physiological aspects of tolerance and physical dependence, in Physiological Pharmacology, Vol. 1 ( W. S. Root and F. G. Hofmann, Eds.), pp. 565–640. Academic Press, New York.
Seevers, M. H., and Woods, L. A., 1953, The phenomena of tolerance, Amer. J. Med. 14: 546–557.
Sharpe, L. G., and Pickworth, W. B., 1980, Pharmacologic evidence for a tonic muscarinic inhibitory input to the Edinger-Westphal nucleus: Relation to morphine-induced miosis in the dog. (in preparation).
Silvestrini, B. and Longo, V. G., 1956, Selective activity of morphine on the ‘BEG arousal reaction“ to painful stimul, Experientia 12:436–438.
Smith, G. M., and Beecher, H. K., 1959, Measurement of “mental clouding” and other subjective effects of morphine, J. Pharmacol. Exp. Ther. 126: 50–62.
Smith, G. M., Semke, C. W., and Beecher, H. K., 1962, Objective evidence of mental effects of heroin, morphine and placebo in normal subjects, J. Pharmacol. Exp. Ther. 136: 53–58.
Tainter, N. L., Tainter, E. G., Lawrence, W. A., Neura, E. N., Lackey, R. W., Ludnea, F. P., Kirland, H. B., and Gonzale, R. I., 1943, Influence of various drugs on the threshold for electrical convulsions, J. Pharmacol. Exp. Ther. 79: 42–53.
Tenney, S. M., and Mithoefer, J. C., 1953, The respiratory depressant action of N-allylnormorphine in the normal subject and in patients with respiratory acidosis secondary to pulmonary emphysema, New Engl. J. Med. 249: 886–890.
Wang, S. C., and Glaviano, V. V., 1954, Locus of emetic action of morphine and hydergine in dogs, J. Pharmacol. Exp. Ther. 111: 329–334.
Weijlard, J., and Erickson, A. E., 1942, N-allylnormorphine, J. Amer. Chem. Soc. 64: 869–870.
Wikler, A., 1944, Studies on the action of morphine on the central nervous system of the cat, J. Pharmacol. Exp. Ther. 80: 176–187.
Wikler, A., 1950, Sites and mechanisms of action of morphine and related drugs in the central nervous system, Pharmacol. Rev. 2: 435–506.
Wikler, A., 1951, Effects of large doses of N-allylnormorphine in man, Fed. Proc. 10: 345.
Wikler, A., 1952a, A psychodynamic study of a patient during self-regulated re-addiction to morphine, Psychiat. Quart. 260: 270–293.
Wikler, A., 1952b, Reactions of dogs without neocortex during cycles of addiction to morphine and methadone, Arch. Neurol. Psychiat. (Chicago) 67: 672–684.
Wikler, A., 1953, Opiate Addiction: Psychological and Neurophysiological Aspects in Relation to Clinical Problems, pp. 27–28. Charles C Thomas, Springfield, Ill.
Wikler, A., 1954, Clinical and electroencephalographic studies on the effects of mescaline, N-allylnormorphine and morphine in man, J. Nero. Ment. Dis. 120: 157–175.
Wikler, A., and Altschul, S., 1950, Effects of methadone and morphine on the electroencephalogram of the dog, J. Pharmacol. Exp. Ther. 98: 437–446.
Wikler, A., and Carter, R. L., 1953, Effects of single doses of N-allylnormorphine on hindlimb reflexes of chronic spinal dogs during cycles of morphine addiction, J. Pharmacol. Exp. Ther. 109: 92–101.
Wikler, A., and Pescor, F. T., 1954, Clinical and electroencephalographic effects of drugs in man and dog, Trans. Amer. Neurol. Ass. 79th Annual Meeting, pp. 170–172.
Wikler, A., Pescor, M. J., Kalbaugh, E. M., and Angelucci, R. J., 1952, The effects of frontal lobotomy on the morphine abstinence syndrome in man: An experimental study, Arch. Neurol. Psychiat. (Chicago) 67: 510–521.
Wikler, A., Fraser, H. F., and Isbell, H., 1953, N-allylnormorphine: Effects of single doses and precipitation of acute “abstinence syndromes” during addiction to morphine, methadone or heroin in man (post-addicts), J. Pharmacol. Exp. Ther. 109: 8–20.
Williams, E. G., and Oberst, F. W., 1946, A cycle of morphine addiction. Part I. Biological investigations, Pub. Health Reports 61: 1–25.
Winter, C. A., and Flataker, L., 1951, The effect of cortisone, desoxycorticosterone and adrenocorticotrophic hormone upon the responses of animals to analgesic drugs, J. Pharmacol. Exp. Ther. 103: 93–105.
Woods, L. A., 1956, The pharmacology of nalorphine (N-allylnormorphine), Pharmacol. Rev. 8: 175–198.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1980 Plenum Press, New York
About this chapter
Cite this chapter
Wikler, A. (1980). Opioid Analgesics and Opioid Antagonists. In: Opioid Dependence. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-3866-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4684-3866-6_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-3868-0
Online ISBN: 978-1-4684-3866-6
eBook Packages: Springer Book Archive